Search results for "remission"

MR-Mammographie zur Responsekontrolle bei primärer Chemobrachytherapie des BET-inoperablen Mammakarzinoms

2001

Ziel: Evaluierung (1) moglicher storender Effekte neoadjuvanter Chemobrachytherapie auf die MR-Mammographie, (2) der Eignung der MRM zur Bestimmung der Resttumorgrose nach Therapie und (3) der Eignung der MRM zur Prognose des Gesamtansprechens nach den ersten Therapiezyklen. Methoden: 14 Patientinnen, die an einer praoperativen Tumorreduktionstherapie (4 Zyklen Chemotherapie kombiniert mit interstitieller Radiotherapie) teilnahmen, wurden mittels dynamischer MR-Mammographie (1 T, zeitliche Auflosung 93 s, raumliche Auflosung 1,9 mm, 0,1 mmol/kg GdDTPA) vor Therapie, nach den ersten beiden Chemotherapiezyklen, nach der Radiotherapie und dem dritten Zyklus sowie nach Therapieabschluss untersu…

A framework for remission in SLE

2017

ObjectivesTreat-to-target recommendations have identified ‘remission’ as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.MethodsAn international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.ResultsThe task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission wi…

Tinea imbricata in Papua-Neuguinea: Behandlungsversuch mit Griseofulvin und Haloprogin bei einer Population des Gogol-Valley, Madang Province

2009

Zusammenfassung: In zwei Dorfern des Gogol Valley (Papua-Neuguinea) wurden satliche 47 an Tinea imbricata erkrankten Personen erfas, wovon 39 einer Griseofuhin®- bzw. Mycan-den®-Therapie oder Kombination zugefuhrt wurden. Die Zuweisung zu den unterschiedlichen Behandlungsgruppen erfolgte anhand des Alters und des prozentualen Befalls der Korperoberflache. Die Therapiedauer betrug maximal 4 Wochen, der Beobachtungszeitraum insgesamt 6 Wochen. Eine Remission des Hautbefalls erfolgte fur beide Therapeutika von der 2. Behand-lungswoche an. Rezidive traten jedoch schon 1 Woche nach Therapieende auf. Es konnten Unterschiede in der Altersverteilung der Erkrankten in beiden Dorfern festgestellt wer…

Remission phase in children diagnosed with type 1 diabetes (T1D) in years 2012-2013 in Silesia, Poland – an observational study

2019

Background/Objective The study aimed to analyze the frequency of partial remission (PR) and its association with chosen clinical and laboratory factors among pediatric patients with newly diagnosed type 1 diabetes (T1D). The long‐term effect of PR on chosen parameters was also investigated. Methods In 194 patients (95 girls) aged 8.1 ± 4.3 years, we analyzed data at T1D onset: glycemia, pH, C‐peptide, antibodies, weight, and concomitant autoimmune diseases. Anthropometric parameters, daily insulin requirement (DIR), and HbA1c 2 and 4 years after T1D diagnosis were also analyzed. We determined PR based on HbA1c and DIR measurements at least every 3 months. Results PR occurred in 59% of patie…

Small Things, Micro-Affirmations and Helpful Professionals Everyday Recovery-Orientated Practices According to Persons with Mental Health Problems

2018

The aim of this study is to present concrete descriptions of the content in the construction of helpful relationships with staff, according to users. Starting with the re-occurring concept of the meaning of "little things" in recovery studies, a literature review was done. A thematic analysis shows that small things play an important role in improving a person's sense of self. Small things seem to be an invisible but effective parts of a recovery-orientated practice, but they might be defined as unprofessional and their efficacy negated.

Spontaneous Remission of Recalcitrant Warts in Girls After Human Papillomavirus Vaccination

2016

A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma.

1989

Recent preclinical and clinical studies that have demonstrated antitumor activity of high-dose recombinant interleukin-2 (rIL-2), and animal models that demonstrated a synergistic effect of low-dose cyclophosphamide, led us to study rIL-2 (Cetus Corp., Emeryville, Calif) in a phase II clinical trial in combination with low-dose cyclophosphamide in 32 patients, 18 with malignant melanoma and 14 with renal cell carcinoma. rIL-2 was given once daily at 3 x 10(6) U/m2, as a 30-min infusion for 14 days in cycle I and for 2 x 5 days in cycles II and III respectively; if tolerated, the dose was increased to a maximum of 6 x 10(6) U m-2 day-1; the cycles, separated by 1 week treatment-free interval…

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

2007

Abstract The increasing evidence that γδ T cells have potent antitumor activity suggests their value in immunotherapy, particularly in areas of unmet need such as metastatic carcinoma. To this end, we initiated a phase I clinical trial in metastatic hormone-refractory prostate cancer to examine the feasibility and consequences of using the γδ T-cell agonist zoledronate, either alone or in combination with low-dose interleukin 2 (IL-2), to activate peripheral blood γδ cells. Nine patients were enlisted to each arm. Neither treatment showed appreciable toxicity. Most patients were treated with zoledronate + IL-2, but conversely only two treated with zoledronate displayed a significant long-te…

Spontaneous tumour regression in keratoacanthomas is driven by Wnt/retinoic acid signalling cross-talk

2014

A fundamental goal in cancer biology is to identify the cells and signalling pathways that are keys to induce tumour regression. Here we use a spontaneously self-regressing tumour, cutaneous keratoacanthoma (KAs), to identify physiological mechanisms that drive tumour regression. By using a mouse model system that recapitulates the behaviour of human KAs, we show that self-regressing tumours shift their balance to a differentiation programme during regression. Furthermore, we demonstrate that developmental programs utilized for skin hair follicle regeneration, such as Wnt, are hijacked to sustain tumour growth and that the retinoic acid (RA) signalling pathway promotes tumour regression by …

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma : Final …

2016

Purpose Blinatumomab is a CD19/CD3 BiTE (bispecific T-cell engager) antibody construct for the treatment of Philadelphia chromosome–negative acute B-lymphoblastic leukemia. We evaluated blinatumomab in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Patients and Methods This 3 + 3 design, phase I dose-escalation study determined adverse events and the maximum tolerated dose (MTD) of continuous intravenous infusion blinatumomab in patients with relapsed/refractory NHL. Blinatumomab was administered over 4 or 8 weeks at seven different dose levels (0.5 to 90 μg/m2/day). End points were incidence of adverse events, pharmacokinetics, pharmacodynamics, and overall response rate. Results B…